Cepheidin Global Access -ohjelma

Globaali vaikuttavuus

Revolution for
A Better Way

Cepheid’s Global Access program started in 2011 with the vision for equitable access to revolutionary new molecular diagnostics. Today, Cepheid’s Global Access program reaches every corner of the globe impacted by deadly diseases like Tuberculosis (TB) and HIV and Ebola.

“Xpert MTB/RIF moved diagnosis from weeks to hours – enabling patients to be treated far more quickly. We have invested heavily in these innovations and will continue to invest in new products critical to eradicating disease.”

David Persing
SVP and Chief Medical
& Technology Officer

Empowering Global Health Solutions

Cepheid’s ongoing commitment to invest and innovate continues to improve the standard of care for communities in low- and middle-income countries. Here is how Cepheid makes a difference:

1

The Innovation Revolution

2

Fostering Partnerships

3

Access and Deployment

1

The Innovation Revolution

Cepheid’s Lab in a Cartridge™ remains a state-of-the-art molecular diagnostics innovation—replacing multiple large laboratory rooms with small cartridge chambers. Cepheid's groundbreaking Xpert MTB/RIF test was the most significant TB diagnostic innovation in nearly a century, and was quickly endorsed by the WHO¹ and heralded by the global community as a game changing diagnostic weapon.

“At a global level, 38% of people newly diagnosed with TB in 2021 were diagnosed with a WHO-recommended diagnostic test, while in 2022, the number rose to 47%. These instruments have been a game-changer.³”

Message from the Executive Director

Global Fund Investments in Health and Laboratory-related Equipment

Lue lisää

GeneXpert: Innovation in Action

Learn how Cepheid’s innovative approach dramatically impacts patient care.*

* Not all systems shown available worldwide.

2

Fostering Partnerships

Cepheid’s technology has played a major role in the foundation of economic recovery across low- and middle-income countries. However, it’s the coordinated efforts of donors, policymakers, governments, NGOs, and national and local health systems that are helping change health initiatives to maximize impact. In fact, a recent health economic analysis found that for every $1 of spend on TB programs the result was $46 in economic impact in country².

“TB is not just a health issue—it is an economic issue, a development issue, and a security issue, and we need strong collaborative efforts from heads of states, private and public sector to really move the needle. We need far more diagnosis, treatment, and prevention. We need more funding, more programs to address barriers to access and more political commitment to help the people who need it most.⁴”

Peter Sands

Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria

Lue lisää

Making a Difference

"I want to leave a legacy...the children of our children will forget about tuberculosis."

Budi Gunadi Sadikin

Minister of Health

Republic of Indonesia

3

Access and Deployment

With over 20 000 GeneXpert systems installed across HBDC, there isn’t a national algorithm in a high burden country that doesn’t incorporate GeneXpert as the basis of its TB response. In September of 2023, Danaher (Cepheid's parent company) raised the company’s joint commitment to End TB by 2030, delivering all future Xpert MTB Ultra cartridges at cost (no profit). Universally welcomed across National TB Programs globally, this price reduction further expands access to the technology and the overall impact of the Global Access Program.

Ohjelman historia

2006

Cepheid asettaa ensimmäiseksi GeneXpert® -järjestelmät

2006

WHO käynnistää tuberkuloosin lopettamisstrategian maailman tuberkuloosipäivänä

2006

Cepheid, FIND, University of Medicine and Dentistry of New Jersey (Rutgers University), and NIAID collaborate to develop Xpert® MTB/RIF* for TB with a grant from the Bill & Melinda Gates Foundation

2009–2010

Xpert MTB/RIF* lanseerataan ja saa WHO:n hyväksynnän

Globaali vaikuttavuus

2011

Cepheid perustaa virallisesti Global Access Program -ohjelman

2006

Vastauksena suureen tuberkuloosi-HIV-koinfektioiden määrään Global Access -hankkeen maissa Cepheid- ja FIND ryhtyvät yhteistyöhön Xpert-HIV-1-viruskuorma* -testin kehittämiseksi.

2014

Xpert® HPV* and Xpert HIV-1 VL* tests launch

2015

Cepheid develops and launches Xpert® Ebola test to respond to West African outbreak with funding support from the Paul G. Allen and Bill & Melinda Gates Foundations

2016

WHO prequalifies Xpert HIV-1 Qual*

2017

WHO prequalifies Xpert HCV VL*, Xpert HIV-1 VL*, and Xpert HPV*; Xpert® MTB/RIF Ultra* launches and gets WHO endorsement

2020

Xpert® MTB/XDR* launches to detect multidrug-resistant TB with new 10-color multiplexing technology

2020

Xpert® Xpress SARS-CoV-2" launches

Global Access -ohjelma tänään

GeneXpert systems available in multiple modular configuration options 15 tests available under Global Access Program, 7 of which are endorsed or pre-qualified by WHO

* CE-IVD. In vitro -diagnostinen lääkinnällinen laite. Ei välttämättä saatavilla kaikissa maissa. Ei saatavilla Yhdysvalloissa.

IVD. In vitro -diagnostinen lääkinnällinen laite. Ei ole välttämättä saatavilla kaikissa maissa

^ Käytössä hätäkäyttöluvan (EUA) nojalla Yhdysvalloissa

Dr. Tereza Kasaeva, Director, Global Tuberculosis Programme, WHO World TB Day 2023, Interview with Dr. Tereza Kasaeva
https://www.youtube.com/watch?v=AL_t8LZkD8Y

1. https://www.who.int/publications/i/item/9789241506335

2. Journal of Benefit-Cost Analysis (2023) https://www.cambridge.org/core/journals/journal-of-benefit-cost-analysis/article/one-million-lives-saved-per-year-a-costbenefit-analysis-of-the-global-plan-to-end-tuberculosis-20232030-and-beyond/A74F0D10F1017092A250EB604ED39B1B

3. Message from the Executive Director: Global Fund Investments in Health and Laboratory-related Equipment; 21. tammikuuta 2024
https://www.theglobalfund.org/en/oig/updates/2024-01-26-message-executive-director-global-fund-investments-health-laboratory-related-equipment/

4. Peter Sands, Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria.
From the TB Innovation Summit https://www.stoptb.org/news/global-health-and-business-leaders-pledge-major-commitments-to-end-tuberculosis

{{getSidebarNestedSelection() || 'Päävalikko'}}

Sijainti / kieli